Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

The first amylin drug was introduced to the market some 20 years ago ... The Danish drugmaker has already struggled to meet ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

SAN AN­TO­NIO — Zealand Phar­ma, hop­ing to cre­ate the next “foun­da­tion­al” ther­a­py for obe­si­ty, de­tailed more Phase 1 da­ta on its amylin ana­log that was the back ...

Specific hypothalamic nuclei, including the dorsomedial nucleus (DMN), paraventricular nucleus (PVN) and ventromedial nucleus (VMN), serve as control centers for appetite. In animals, lateral ...